Compare FUNC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FUNC | VCRE |
|---|---|---|
| Founded | 1900 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 271.7M |
| IPO Year | 2012 | 2026 |
| Metric | FUNC | VCRE |
|---|---|---|
| Price | $43.81 | $9.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $50.00 | $29.03 |
| AVG Volume (30 Days) | ★ 27.9K | 24.8K |
| Earning Date | 10-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 19.68 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $18,426,000.00 | N/A |
| Revenue This Year | $9.57 | $101.29 |
| Revenue Next Year | $6.10 | $481.15 |
| P/E Ratio | $22.84 | ★ N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $33.54 | $7.88 |
| 52 Week High | $46.30 | $14.01 |
| Indicator | FUNC | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 45.56 |
| Support Level | $43.30 | $8.79 |
| Resistance Level | $45.71 | $12.08 |
| Average True Range (ATR) | 1.12 | 0.85 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 45.13 | 41.50 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.